Plasma is becoming an increasingly popular biological sample to identify diagnostic biomarkers as its protein composition uniquely reflects the body’s physiological state. Recent studies have demonstrated that using MS-based plasma proteomics not only enables the identification of biomarkers but also potential therapeutic targets.
To enhance plasma proteomics research, Biognosys developed the PQ500 Reference Peptides kit. The kit contains an optimized set of 804 SIS peptides that target 582 plasma proteins. The use of heavy labeled reference peptides provides numerous benefits, especially for large-scale plasma analyses that involve large sample cohorts.
In this seminar, Biognosys’ Principal Scientist Sebastian Müller dives into how the use of PQ500 helps overcome typical limitations in large-scale projects, such as repeatability and consistency of results. In addition, PQ500 combined with SureQuant acquisition provides exceptional analytical depth and unmatched quantitative accuracy.
Manuel Mayr, Professor of Cardiovascular Proteomics at King’s College London, highlights the above-mentioned benefits during the presentation of his work using PQ500 in DIA mode and Biognosys’ software Spectronaut to identify biomarkers that predict mortality in COVID-19 patients.
The seminar concluded with a Q&A session chaired by Biognosys’ Fabia Simona.
Short-Bio Manuel Mayr (King’s College London)
Manuel Mayr qualified in Medicine from the University of Innsbruck (Austria) in 1999. He then moved to London to undertake a PhD. Upon completion of his PhD, he achieved promotion to Professor in 2011. He has been awarded a prestigious British Heart Foundation Personal Chair in 2017. His academic achievements have been recognized by the inaugural Michael Davies Early Career Award of the British Cardiovascular Society (2007), the inaugural Bernard and Joan Marshall Research Excellence Prize of the British Society for Cardiovascular Research (2010), the Outstanding Achievement Award by the European Society of Cardiology Council for Basic Cardiovascular Science (2013) and the President’s Distinguished Lecture award of the International Society for Heart Research (2022).
Short-Bio Sebastian Müller (Biognosys)
Sebastian Müller has more than 15 years hands-on experience in applied mass-spectrometry (MS) based proteomics. Prior to joining Biognosys as Product Developer & now Principal Scientist R&D, he employed cutting edge MS technologies in functional protease characterization in an oncological context at the Albert-Ludwigs University in Freiburg (Germany) and in pre-clinical metabolic research at ETH Zurich (Switzerland).